Gilead Sciences, Inc.
GILD Healthcare Drug Manufacturers General
Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.
Follow GILD
Gilead Sciences, Inc. (GILD) Return on invested capital
Gilead Sciences, Inc.'s return on invested capital over the twelve months to 30 June 2026 was −4.48%, down 20.2 percentage points from fiscal 2025 (15.7%). Over the past ten years it has ranged from 2.89% (fiscal 2024) to 51.5% (fiscal 2015); the current reading is higher than 64% of that period. That is below the Drug Manufacturers General industry median of 6.11% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 15.7% | 12.80 |
| FY2024 | 2.89% | (8.49) |
| FY2023 | 11.4% | 0.27 |
| FY2022 | 11.1% | (3.57) |
| FY2021 | 14.7% | 8.82 |
| FY2020 | 5.86% | (5.35) |
| FY2019 | 11.2% | (14.66) |
| FY2018 | 25.9% | (4.47) |
| FY2017 | 30.3% | (1.97) |
| FY2016 | 32.3% | (19.14) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NVO Novo Nordisk A/S compare | 28.7% |
| BMY Bristol Myers Squibb Company compare | 13.7% |
| NVS Novartis AG compare | 13.1% |
| AMGN Amgen Inc. compare | 13.0% |
| GSK GSK PLC Sponsored ADR compare | 12.6% |
| AZN AstraZeneca PLC compare | 11.7% |
| PFE Pfizer Inc. compare | 6.30% |
| MRK Merck & Co., Inc. compare | 5.08% |
| GILD Gilead Sciences, Inc. | −4.48% |
| Drug Manufacturers General industry median | 6.11% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on GILD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement